Phase 1/2a clinical trial completed in Korea62%
Cleared US FDA Phase I/2 IND45%
Treatment of Alzheimer’s Disease
NEUROSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is under development for the treatment of Alzheimer’s Disease. Phase 2a clinical trial has been completed as of December 2019 after successfully completing the Phase 1 clinical trial in Korea.
|· Product :||NEUROSTEM® |
(human Umbilical Cord Blood-derived
Mesenchymal Stem Cells)
|· Manufacturer :||MEDIPOST Co., Ltd.|
|· Indication :||Treatment of Alzheimer's disease|
|· Route of Administration :||Intra-ventricular administration|
Before and after the administration of NEUROSTEM® (animal experiments)
NEUROSTEM® Mechanism of Action video
The accumulation of β-amyloid in the brain, which causes Alzheimer-type dementia, induces learning and memory disorder by damaging the nerve cells. Once NEUROSTEM® is administrated to the patient’s brain with Alzheimer-type dementia, the umbilical cord blood-derived mesenchymal stem cells migrate towards the injury signals within the damaged brain and secrete proteins which stimulate microglia cells. The stimulated microglia cells promote the degradation of β-amyloid by secreting β-amyloid degrading enzymes.
Mechanism of Action for NEUROSTEM®